Aprea Q2 2026: net loss $3.6M, cash $41.2M, APR-1051 enrollment accelerating

Aprea Therapeutics, Inc.

Cash $41.2M at June 30, 2026 vs $14.6M at Dec 31, 2025; runway into Q1 2028.
Net loss $3.6M ($0.07/share) on 53.5M shares vs $3.2M ($0.53/share) on 6.1M shares in Q2 2025.
APR-1051 Phase 1 trial sites expand 3 to 10; enrollment 6-10 patients/month by Q4 2026; next data at Q4 2026 medical meeting.
Plans to advance APR-1051 in USC and Cyclin E-overexpressing PROC; combinations in HPV+ head/neck and colorectal cancer.
$30M private placement closed Q1 2026; ATRN-119 study closed, combinations under discussion.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.